Problem

Deep brain stimulation (DBS) is already an FDA-approved therapy for Parkinson’s disease, essential tremor, dystonia, and drug-resistant epilepsy, but conventional systems can stimulate tissue outside the intended target. That off-target stimulation can create side effects and limit long-term efficacy, making it difficult to deliver the right therapy with sufficient precision. The clearest use case is improving DBS for patients who benefit from stimulation but are constrained by side effects, imprecise targeting, or declining therapeutic response.

Current commercial DBS systems generally stimulate continuously without sensing local neural activity. As the brain becomes less responsive, patients may need repeated programming visits, which are time-consuming and stressful, while continuous stimulation drains the implanted battery and can lead to replacement surgery. The economic burden is substantial: one review found that the mean U.S. cost of the DBS device and surgery was about $53,266. Torpedo is therefore addressing both clinical pain and the maintenance cost of a high-value but invasive treatment.

Product / Service

Torpedo is developing an implantable, high-precision, closed-loop neuromodulation platform rather than a conventional open-loop DBS device. Its electrode leads use micro- and nano-fabrication to pack many individually addressable microelectrodes into a very small lead; the company says the individual electrodes are about 150 times smaller than existing DBS lead electrodes and can stimulate at approximately single-neuron precision while still covering larger brain regions when needed.

The system is designed to continuously sense neural activity during stimulation and automatically adjust stimulation parameters based on those signals. The platform combines high-density microelectrode leads, on-lead readout and stimulation electronics, and machine-learning software for neural-signal analysis and control. The intended benefits are more targeted stimulation, fewer side effects, better personalization and long-term efficacy, fewer ad hoc programming visits, lower battery consumption, and eventually a smaller alternative to the bulky implanted pulse generators used in current systems.

Market

Torpedo competes in medical devices, neurotechnology, and the deep-brain-stimulation market, with a particular focus on adaptive or closed-loop neuromodulation. Its direct commercial comparators are the established DBS manufacturers Abbott, Boston Scientific, and Medtronic, which are identified as the three U.S. DBS device makers. Torpedo’s differentiation is not that it makes DBS available for a new disease, but that it aims to improve the precision, sensing, automation, and form factor of the existing treatment category.

The company appears to be an early-stage, pre-commercial or early-commercialization venture rather than a scaled device business. Public profiles describe it as active, cite acceptance into Y Combinator’s Winter 2022 batch, list its product as being in beta testing, and report approximately $920,000 raised. Revenue is not clearly established: PitchBook leaves current revenue blank, while another third-party estimate claims $1 million of 2024 revenue. The most defensible characterization is therefore an active development-stage company with ecosystem and financing traction, but without public evidence of regulatory clearance, broad clinical adoption, or dependable commercial revenue.